Anuh Pharma Limited Q2 FY26 results deck summary

Results deck of 17 Nov 2025, summarised by AI from the filing.

H1 FY26 revenue ₹376.73 cr (+21.14% YoY) but EBITDA fell to ₹20.87 cr (-31.47%) on lower high-margin product sales.

Key takeaways

1. Growth target Company anticipates a steady growth rate of 15-16% per annum.
2. Margin decline H1 FY26 EBITDA margin 7.13% vs H1 FY25 11.38%, on lower high-margin product sales, maintenance and currency losses.
3. Capacity expansion Added a new intermediate block, taking total to 2 intermediate blocks and 9 API blocks, with total reactor capacity at 240 KL.
4. Margin risk Lower sales of certain high-margin products reduced contribution, with expected recovery in the second half.

Original filing on BSE

Anuh Pharma Limited Q1 FY27 results

As filed: Revenue ₹194 cr (+4% year on year), EBITDA ₹16.3 cr (+48% year on year), PAT ₹11.4 cr (+43% year on year), EBITDA margin 8.4% (+249 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹202 cr (+2% year on year), EBITDA ₹19.9 cr (+5% year on year), PAT ₹11.7 cr (−3% year on year), EBITDA margin 9.8% (+24 bps). Score 35 of 100, Below trend. EBITDA margin rose 24 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 13% from last quarter. Share price after the results: −4.4% in 30 days (Nifty 500: +2.5%).
• Q3 FY26: Revenue ₹197 cr (+23% year on year), EBITDA ₹16.8 cr (+20% year on year), PAT ₹13.5 cr (+35% year on year), EBITDA margin 8.5% (−23 bps). Score 68 of 100, Above trend. EBITDA margin fell 23 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −2.1% in 28 days (Nifty 500: −4.1%).
• Q2 FY26: Revenue ₹186 cr, EBITDA ₹12.0 cr, PAT ₹8.0 cr, EBITDA margin 6.5%. Not scored. No result for the same quarter last year. Share price after the results: −4.3% in 28 days (Nifty 500: +1.3%).
• Q1 FY26: Revenue ₹186 cr, EBITDA ₹11.0 cr, PAT ₹8.0 cr, EBITDA margin 5.9%. Not scored. No result for the same quarter last year. Share price after the results: −7.0% in 28 days (Nifty 500: +1.7%).
• Q4 FY25: Revenue ₹198 cr, EBITDA ₹19.0 cr, PAT ₹12.0 cr, EBITDA margin 9.6%. Not scored. No result for the same quarter last year. Share price after the results: −0.4% in 28 days (Nifty 500: +1.1%).
• Q3 FY25: Revenue ₹160 cr, EBITDA ₹14.0 cr, PAT ₹10.0 cr, EBITDA margin 8.8%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Anuh Pharma Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Results deck (19 Aug 2026)
• Q4 FY26: Results deck (28 May 2026)
• Q3 FY26: Results deck (13 Feb 2026)
• Q2 FY26: Results deck (17 Nov 2025)
• Q1 FY26: Results deck (22 Aug 2025)
• Q4 FY25: Results deck (29 May 2025)